Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML

  • Alison R. Walker
  • , Rami S. Komrokji
  • , Jainulabdeen Ifthikharuddin
  • , Patti Messina
  • , Deborah Mulford
  • , Michael Becker
  • , Jonathan Friedberg
  • , Jamie Oliva
  • , Gordon Phillips
  • , Jane L. Liesveld
  • , Camille Abboud

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Fingerprint

Dive into the research topics of 'Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science